Medi-Cal AWP fraud suit expands
Executive Summary
California Attorney General sues 39 pharmaceutical manufacturers for reporting inflated prices to the state's Medi-Cal Medicaid program. The suit, filed Aug. 25 in U.S. District Court in Boston, is an expansion of a 2003 California whistleblower suit against Abbott and Wyeth. Suit adds 38 defendants; Wyeth was dropped from the list of defendants after further investigation, the AG's office said. The defendant includes a variety of manufacturers: including both brand firms (Amgen, GlaxoSmithKline, Bristol-Myers Squibb and Novartis) as well as generic firms (Roxane, Mylan, Sandoz and Teva). Notably absent from the suit are Lilly, Merck, Pfizer and Johnson & Johnson. The suit alleges that the firms defrauded the state by reporting inflated wholesale prices to pricing compendia, which Medi-Cal used to determine physician reimbursement rates. California is one of a number of states suing manufacturers for pricing fraud based on data provided by whistleblowing pharmacy Ven-A-Care (1"The Pink Sheet" Oct. 1, 2001, p. 12)...
You may also be interested in...
Merck, Lilly, J&J Pricing Practices Praised By AWP "Whistleblower"
Merck, Lilly, Johnson & Johnson and DuPont are examples of manufacturers who do not market the "spread" between average wholesale prices and actual prices, Ven-A-Care President Zachary Bentley told a Congressional hearing on AWPs Sept. 21.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.